Sekar Kathiresan, Verve Therapeutics CEO
November 7, 2022 07:25 AM ESTUpdated 07:44 AM
R&D
Cell/Gene Tx
FDA+

Up­dat­ed: Verve's land­mark base edit­ing tri­al for car­dio drug runs in­to FDA hold

Max Gelman

Senior Editor

Four months af­ter kick­ing off the first-ever base edit­ing tri­al in hu­mans, Verve Ther­a­peu­tics is run­ning up against a reg­u­la­to­ry wall.

The FDA placed Verve …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times